Is it useful to take targeted drugs when cancer has ascitic fluid? What to do?
Some targeted drugs were useful for cancer ascitic fluid. For example, bevaczhu, as a targeted drug, could effectively reduce the accumulation of fluid in the abdominal cavity through abdominal infusion through combination chemotherapy, maintaining the balance of water in and out of the blood vessels, and thus controlling the production of abdominal fluid. Sorafenib or lenvatini could have a certain effect on the treatment of liver cancer, liver cancer, and hepatic ascitic fluid caused by liver cancer, but it might not be effective. If a cancer patient had ascitic fluid and was taking targeted drugs, if they had poor appetite, abdominal distension, etc., it might be the stimulation of the targeted drugs on the digestive tract mucus, resulting in abnormal secretion of gastric acid and digestive hormones, and slow intestinal distension. First, it can be determined whether there is a time relationship between poor appetite, abdominal distension, and taking targeted drugs. If there is a time relationship, the following measures can be taken: 1. Under the guidance of the doctor, take Jianwei Xiaoshi tablets, moperlin tablets, and digestive tablets. 2. You can take Chinese patent medicine Baohe pills and Xiangsha Yangwei pills (Chinese medicine is suitable for liver and stomach disharmony). 3. He massaged his abdomen, using a technique of pushing and rolling from top to bottom. If the abdominal distension is not relieved after the above measures are used, the body weight and abdominal circumference should be measured first to find out whether there is ascitic fluid, and the liver and kidney function should be rechecked to find out whether there is hepatic incompetence. Sometimes, in patients with liver tumors or previous liver cancer, taking targeted drugs would lead to an increase in ascitic fluid, which would lead to slow down of the digestive system. If the increase of ascitic fluid causes poor appetite and abdominal distension, you can ask the relevant doctor for help to protect the liver, diuretics, and protein replenishment. If it's just abnormal liver function that causes loss of appetite, you should actively treat liver protection. In addition, traditional Chinese medicine could also help in the auxiliary treatment of advanced cancer complicated with large amounts of ascitic fluid. For example, the prescription with poria cocos, grifola, lycopus, danshen, and milkvetch root as the main components was good at reducing water and swelling, helping to regulate the water balance in the body and reducing the discomfort caused by ascitic fluid. However, traditional Chinese medicine emphasized the treatment based on syndrome identification, so it was necessary to formulate an individual plan according to the patient's different conditions and physique. The prescription medicine must be used under the guidance of a professional doctor. Under the premise of using medication to control the ascitic fluid, it was necessary to actively treat the primary disease, strengthen nutrition, and eat more foods with high protein and vitamins. If the patient had any adverse reactions during the use of the targeted drug, they should immediately go to a regular hospital for treatment to avoid delaying the condition. Read more exciting novels for free
Is it useful to take targeted drugs for esophagus cancer metastasizing?
At present, a variety of targeted drugs were available for the treatment of esophagus cancer, including new small molecules multi-target Tyrosin Kinase Inhibition, drugs that targeted HEL2, cetuxed that targeted the egFr target, and bevacizumb that targeted the veg-like growth factor target, etc. There was also a combination of PD1 - 1 inhibition and targeted HEL2 for the treatment of cancer at the gastric-esophagus junction. Chinese studies have shown that as a new small-molecular multi-target Tyrosinase Kinase Inhibition, anlotinib and apitini have a certain effect in the treatment of esophagus cancer. The combination therapy of trastuzumab-targeted to HEL2 and PD1 inhibition drugs (such as pembrolizumab) combined with chemotherapy can be used as the first-line treatment for cancer of the gastroesophagus junction, advanced gastric cancer with HEL2 positive, and esophagus cancer. In the second-line treatment of China guidelines for the treatment of esophagus cancer, level II recommendations were given to anlotinib (Class 2A) and apitini (Class 3). However, there were no phase III clinical trials to prove that molecular targeted drugs could prolong the survival of patients with esophagus cancer. The effect of targeted therapy needed further study. In general, molecular targeted therapy had a certain clinical value for the treatment of patients with esophagus cancer, including those with metastasizing, but it still needed further in-depth research. These drugs must be used under the guidance of a professional doctor. It is not recommended for patients to buy and take them themselves to avoid serious adverse reactions. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it always effective to take targeted drugs for lung cancer?
The effect of targeted drugs on lung cancer patients was not very good. Target drugs could not cure lung cancer. Although they could prolong survival time, they could not always be effective. There were very few driver mutations in lung cancer, so there were relatively few targeted drugs that could be used. When using targeted drugs, it was necessary to find the target of lung cancer and could not be used blindly. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long will it take for targeted drugs to be effective for lung cancer?
Patients with lung cancer usually took targeted drugs for ten days, no more than forty days, and the effect would take effect in two to three days. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it useful to take targeted drugs after chemotherapy and discharge? How long?
Compared with traditional chemotherapy drugs, anti-tumor targeted drugs had a completely different mechanism of action. At the same time, they had the significant advantages of high efficiency, low toxicity, and strong specialization. It was useful to use targeted drugs after discharge from chemotherapy, but the specific duration of effect would be affected by many factors. The drug resistance of targeted drugs was an important factor that affected their duration of action. Cancer cells would mutate. Although targeted drugs could accurately attack cancer cells, they could not identify all cancer cells in all directions. It was easy for drug resistance to occur. When cancer cells develop drug resistance, the effect of the targeted drug will decrease, and at this time, the drug may need to be changed. In order to detect drug resistance problems in time, regular assessment tests, such as tissue examination and blood test, were needed to adjust the medication in time. The individual differences between different patients would also affect the duration of the targeted drug. For cancer patients with specific gene mutations, such as cancer patients with egf-mutation, the targeted drug treatment effect would be more prominent, and the drug efficiency could reach 70%. Before targeted therapy, a comprehensive assessment was needed to understand whether there were specific changes in the genes. Patients who met the conditions would have a better effect if they used targeted drugs. In addition, the way the targeted drug was taken would also affect its effect and duration of effect. For example, the drug should be administered at the same time every day. This would allow the targeted drug to release a stable concentration of the drug, allowing the human body to absorb the drug's effects more deeply. If the timing of taking the medicine was messed up, the concentration of the medicine could not be released stably, which might affect the treatment effect. In short, taking targeted drugs after hospitalization was useful, but it was difficult to determine how long it would last. It was necessary to consider various factors such as drug resistance, individual differences, and medication methods. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long do you take targeted drugs for lung cancer?
The time taken for targeted treatment of lung cancer needed to be considered from both the patient's own condition and the progression of the disease. For patients with middle-stage lung cancer, it is recommended to take the first-generation targeted drug for 1.5 - 2 years or the third-generation targeted drug for 3 years. For patients with advanced lung cancer, as long as the targeted drug was effective, it was recommended to take it until the disease progressed. If drug resistance appeared, the targeted drug would need to be replaced. However, it should be noted that the premise of using targeted drugs was that the patient must have a clear target for treatment in the body, and there must be a specific drug targeting the target before targeted drug therapy could be carried out. Less than 20% of lung cancer patients could find targeted drugs. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
There are several types of breast cancer targeted drugs
There were mainly the following types of breast cancer targeted drugs: 1. Anti-neoplastic targeted drugs: There are intravenous preparations and oral drugs, but the effect in the treatment of breast cancer is not ideal. For example, bevacidol (Avastin) will be considered in some cases. 2. Anti-Her- 2 targeted drugs: targeted at HER - 2 positive patients, it is the most important targeted drug for breast cancer, mainly including trastuzumab (Herceptin), pertubizab, dm- 1, lapatini, etc. The prerequisite for use was that the patient was positive for HER - 2 (+++ in the immune tissue test). If the immune tissue test was ++, the patient would need to undergo a further FISH test. The patient could only be used if the FISH test was positive. If the immune tissue test was + or-, the patient could not be used. 3. A targeted drug for patients with fetal mutations in the Brca lineage: The main drug is olaparib, which is used to treat patients with metastasizing breast cancer who have harmful or suspected harmful mutations in the Brca lineage and who are negative for the human embryonic growth factor receptor 2 (HEL2). 4. Immune therapy (in a sense, it was also a targeted drug): Anti-PD- 1/PD-L1 Monoclone Antibodies, which essentially relieved immune suppression and activated immune cells to kill cancer cells. 5. mTO inhibition drugs, such as everolimus and sirolimus, can inhibit the activation of the mTO signaling pathway, thereby suppressing the growth and metabolism of tumor cells. 6. Other targeted therapy drugs, such as Parp inhibition drugs, CD 4/6 inhibition drugs, etc. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Triple-positive breast cancer, is it useful for women to take hormonal drugs?
It was useful for women with triple positive breast cancer to take hormonal drugs. Triple-positive breast cancer meant that the three indicators of the estrogen receptor, the hormone receptor, and the human embryonic growth factor receptor 2 were all positive. Because the estrogen receptor and the hormone receptor were positive, they could choose to use hormone therapy. For example, tamoxifen could be considered for hormonal therapy in pre-menstrual patients, and drugs such as alatrozuo, letrozuo, and eximestane could be considered for post-menstrual patients. The hormone therapy could regulate the level of hormones in the patient's body and suppress the growth of tumor cells. In addition, in different stages of treatment for triple positive breast cancer (such as auxiliary therapy, neo-auxiliary therapy, late-stage treatment, etc.), the combination of hormone therapy and other treatments (such as targeted therapy, etc.) could improve the treatment effect. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is the targeted drug for liver cancer metastasizing useful?
If liver cancer patients had metastasized, they could use targeted drugs, but they had to pay attention to their own condition. For patients with liver cancer lung metastasizing, they could take targeted drugs such as sorafenib, gefitini, or afatini. Sorafenib was more commonly used to treat untreatable or distant cancerous tumors. However, if there was severe liver function decline, large amounts of ascitic fluid, digestive tract bleeding, hepatic epilepsy, repeated infection, and other conditions, it was not suitable to use targeted drugs. At the same time, although targeted drugs had a certain effect on many liver cancer patients, some patients had no effect at all, and the cost was relatively high. Therefore, it was necessary to choose according to the individual's actual situation. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is the liver in the late stage of ascitic fluid?
Ascites in the liver did not necessarily mean that it was in the late stage. The appearance of ascitic fluid depends on the type and severity of the liver disease. Ascites could be caused by either chronic or acute liver disease. If it was caused by a chronic disease, then it might not immediately show late symptoms, but if it was caused by an acute disease, then it might soon show late symptoms. Therefore, the presence of liver ascitic fluid did not necessarily mean that it had reached the late stage. The final conclusion could only be made after diagnosis and treatment.
Take the third generation of targeted drugs after the first generation of targeted drugs are resistant
After the first-generation targeted drug became resistant, the third-generation targeted drug could be considered. According to the data in document [2], after the first-generation targeted drug became resistant, only about 25% of patients had the opportunity to use osimertinib for second-line treatment. According to the study mentioned in document [4], the first-line use of osimertinib for the treatment of egfr-positive lung cancer, followed by comprehensive treatment methods such as chemotherapy and chemotherapy after drug resistance, the patient's overall survival time was 41.4 months, which was twice as long as the first-generation targeted drug. In addition, the document [5] mentioned the dual-target combination therapy plan, specifically the first-line treatment of the third-generation TKi osimertinib combined with the first-generation TKi gefitini, with a disease control rate of 100%. Therefore, for patients who were resistant to first-generation targeted drugs, third-generation targeted drugs might be an effective treatment option.